Protagonist Therapeutics, Inc Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Protagonist Therapeutics, Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Protagonist Therapeutics, Inc Operating Income (Loss) for the quarter ending June 30, 2024 was -$38.8M, a 8.41% increase year-over-year.
  • Protagonist Therapeutics, Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was $152M.
  • Protagonist Therapeutics, Inc annual Operating Income (Loss) for 2023 was -$93.7M, a 28.7% increase from 2022.
  • Protagonist Therapeutics, Inc annual Operating Income (Loss) for 2022 was -$131M, a 4.39% decline from 2021.
  • Protagonist Therapeutics, Inc annual Operating Income (Loss) for 2021 was -$126M, a 95.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $152M -$38.8M +$3.56M +8.41% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $149M $206M +$242M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$93.7M $23M +$59.6M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$153M -$38.3M -$6.02M -18.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$147M -$42.4M -$911K -2.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$146M -$36M -$14.9M -70.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$131M -$36.5M +$500K +1.35% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$132M -$32.3M +$1.62M +4.78% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$133M -$41.4M -$10.6M -34.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$123M -$21.1M +$2.91M +12.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$126M -$37M -$18.2M -96.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$108M -$33.9M -$26.2M -337% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$81.5M -$30.9M -$12.7M -69.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$68.8M -$24M -$4.32M -22% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$64.5M -$18.8M -$1.53M -8.85% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-15
Q3 2020 -$63M -$7.77M +$9.4M +54.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$72.4M -$18.2M +$13.2M +42% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$85.6M -$19.7M -$5.05M -34.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$80.5M -$17.3M -$1.89M -12.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-10
Q3 2019 -$78.6M -$17.2M -$7.78M -82.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$70.9M -$31.4M -$22.2M -240% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$48.7M -$14.6M -$6.42M -78% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$42.3M -$15.4M -$11.9M -339% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$30.4M -$9.39M -$4.41M -88.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 -$26M -$9.24M +$5.89M +38.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 -$31.9M -$8.23M +$6.04M +42.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
Q4 2017 -$37.9M -$3.51M +$7.88M +69.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$45.8M -$4.98M +$2.16M +30.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$47.9M -$15.1M -$8.04M -113% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$39.9M -$14.3M -$7.23M -103% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$32.7M -$11.4M -$6.4M -128% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$26.3M -$7.14M -$3.12M -77.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$23.2M -$7.09M -$4.01M -130% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$19.1M -$7.04M -$4.35M -162% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$14.8M -$5M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-07
Q3 2015 -$4.02M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-07
Q2 2015 -$3.08M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-07
Q1 2015 -$2.69M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.